CD4 and central nervous system cancer: Subsequently, Shen and colleagues also saw no significant difference in percentage of TIM-3 positivity on peripheral CD4+ and CD8+ T cells from glioma patients (13 out of 20 were glioblastoma) versus peripheral CD4+ and CD8+ T cells from healthy controls [102].